Kymos Group published a blog article exploring the key analytical challenges associated with Antibody-Drug Conjugates (ADCs)

Kymos Group is an analytical CRO devoted to bioanalysis and CMC services for small molecules, biologics and nucleic acids. We are GMP and GLP certified and we have been inspected by EMA and FDA. We work for biotechnology, pharmaceutical, veterinary, fine chemistry, cosmetics and nutraceutical industries. The company premises are located in Cerdanyola del Vallès (Technology Park) where we have a two stand alone buildings: one of 1,500 m2 for laboratories and a second one of 1,000 m2 for offices. Our labs are fully equipped with state-of-the-art technology. The company has two additional laboratories in Italy and Germany, as well as partnership agreements and collaborations with a wide range of local and multinational companies. Our main areas of activity are: BIOANALYSIS: - Full bioequivalence studies for generics - Bioanalysis of preclinical and clinical samples by mass spec (pK, PD, TK) - Bioanalysis by ELISA and ECLA for biologics and biosimilars - Immunogenicity studies - Cell based assays - Enzyme activity - Nucleic acid bioanalysis by qPCR CMC: - Analytical Method development and Validation - API analysis (compendial and non-compendial methodsI) - Stability studies - Characterization of biologics following the ICH Q6B - Microbiology testing - Batch Testing & Batch Release